Data as of Sep 12, 2026. Both funds on the fields they both publish, from the same sources.
ITOT vs XBI: how they differ
ITOT and XBI hold 2% of their weight in the same names, and XBI returned more over the year.
iShares Core S&P Total U.S. Stock Market ETF and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, ITOT and XBI hold 2% of their money in the same securities at the same weight.
| Holding | ITOT | XBI |
|---|---|---|
| AbbVie, Inc. | 0.61% | 1.04% |
| Amgen, Inc. | 0.27% | 1.00% |
| Gilead Sciences, Inc. | 0.21% | 0.97% |
| Vertex Pharmaceuticals, Inc. | 0.17% | 1.06% |
| Regeneron Pharmaceuticals, Inc. | 0.09% | 0.96% |
| Alnylam Pharmaceuticals, Inc. | 0.06% | 0.96% |
| Natera, Inc. | 0.05% | 1.17% |
| Revolution Medicines, Inc. | 0.05% | 1.21% |
| Biogen, Inc. | 0.04% | 1.03% |
| Moderna, Inc. | 0.03% | 1.41% |
| Insmed, Inc. | 0.03% | 1.08% |
| United Therapeutics Corp. | 0.03% | 0.93% |
| Only in ITOT | Only in XBI |
|---|---|
| NVIDIA Corp. 6.64% | Roivant Sciences Ltd 1.16% |
| Apple, Inc. 5.82% | Alkermes PLC 1.11% |
| Microsoft Corp. 3.80% | Biohaven Ltd 0.53% |
| Amazon.com, Inc. 3.20% | Immix Biopharma Inc 0.20% |
| Alphabet, Inc. 2.87% | Damora Therapeutics Inc 0.17% |
| Broadcom, Inc. 2.45% | MapLight Therapeutics Inc 0.17% |
| Alphabet, Inc. 2.29% | Cabaletta Bio Inc 0.15% |
| Micron Technology, Inc. 1.78% | Prothena Corp PLC 0.13% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026.
| ITOT iShares Core S&P Total U.S. Stock Market ETF | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | iShares | State Street |
| What it is | Core S&P Total U.S. Stock Market | SPDR S&P Biotech |
| Total return, 1 year | +17.2% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | −0.3 pts | +46.5 pts |
| Expense ratio | 0.03% | 0.35% |
| Already in the S&P 500 | 88.3% | 8.5% |
| Holdings | 2497 | 150 |
ITOT in plain words
ITOT is an index equity fund tracking the Core S&P Total U.S. Stock Market. Over the year to Sep 11, 2026 it returned +17.2% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.03% a year. By its holdings filed for Jun 30, 2026, 88% of the fund by weight is stocks the S&P 500 also holds, across 2497 positions, with the top ten at 32.2%.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Jun 30, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 150 positions, with the top ten at 13.3%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, ITOT or XBI?
- In the year to Sep 12, 2026, with distributions reinvested, ITOT returned +17.2% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, ITOT or XBI?
- ITOT charges 0.03% a year and XBI charges 0.35%, so ITOT is cheaper. Fees come from each fund's prospectus.
- How much do ITOT and XBI overlap with the S&P 500?
- By their latest filed holdings, 88% of ITOT and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 2% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, ITOT against XBI, data as of Sep 12, 2026. https://etfiq.com/compare/any/ITOT-XBI Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources